IP Library › Granted Patent US 11,104,746
Granted Patent B2
US 11,104,746 · App. 16/766,369 · Granted Aug 31, 2021

Process for the synthesis of a cyclodextrin derivative

Inventors: Jordi Puig Serrano (Gerona, ES); Jordi Bosch I Llado (Girona, ES); Iteng Ng Choi (Girona, ES); Ernesto Duran López (Barcelona, ES)
Assignee: Medichem, S.A.
C08B37/0012C08L5/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,746
App. No.
16/766,369
Granted
Aug 31, 2021
Kind
B2
Abstract

This invention relates to an improved process for the synthesis of Sugammadex or a salt thereof, to Sugammadex or a salt thereof having high purity as obtained by said process and to pharmaceutical compositions comprising said high purity Sugammadex or a salt thereof.

Claims (31)

1. A process for the preparation of Sugammadex or its salts, which comprises:

a) reacting 3-mercaptopropionic acid of formula (III)

with an ionic base to obtain the mono-salt of formula (IV),

wherein M is an alkaline metal;

b) isolating the mono-salt of formula (IV);

c) reacting the mono-salt of formula (IV) with the compound of formula (II) or a hydrate or solvate thereof, in the presence of an ionic base,

wherein X is Cl, Br, I, or OSO 2 R, wherein R is C 1 -C 4 alkyl, optionally substituted by F, Cl, Br or I; phenyl or C 1 -C 4 alkyl-phenyl.

2. The process according to claim 1 , wherein the Sugammadex salt is Sugammadex sodium.

3. The process according to claim 2 , wherein the mono-salt of formula (IV) is the mono-sodium salt of formula (IV-A)

4. The process according to claim 3 , wherein the mono-sodium salt of formula (IV-A) is characterized by having X-ray powder diffraction (XRPD) pattern comprising peaks at 6.1 and 24.9±0.2° 2-theta (2θ)).

5. The process according to claim 2 , wherein the ionic base of step a) and step c) is a sodium ionic base.

6. The process according to claim 5 , wherein the ionic base of step a) and step c) is sodium hydroxide.

7. The process according to claim 6 , wherein the sodium hydroxide used in step a) and c) is used in solid form.

8. The process according to claim 2 , wherein step a) is carried out in isopropanol.

9. The process according to claim 2 , wherein step c) is carried out in a mixture of N,N-dimethylformamide and methanol.

10. The process according to claim 2 , wherein step c) takes place at a temperature of between 95° C. to 110° C.

11. The process according to claim 10 , wherein step c) takes place for 4 to 8 hours at 95 to 100° C., followed by 8 to 12 hours at 105 to 110° C.

12. The process according to claim 2 , wherein the compound of formula (II) or a hydrate or solvate thereof is selected from the group consisting of 6-per-deoxy-6-per-chloro-γ-cyclodextrin, 6-per-deoxy-6-per-bromo-γ-cyclodextrin and 6-per-deoxy-6-per-iodo-γ-cyclodextrin or a hydrate or solvate thereof.

13. The process according to claim 12 , wherein the compound of formula (II) or a hydrate or solvate thereof is 6-per-deoxy-6-per-chloro-γ-cyclodextrin, compound of formula (II-A)

or a hydrate or solvate thereof.

14. The process according to claim 13 , wherein the compound of formula (II-A) or a hydrate or solvate thereof is prepared by a process comprising the following steps:

a) reacting a sulfonyl chloride with a tertiary amide compound to form a Vilsmeier reagent; and

b) reacting the Vilsmeier reagent with γ-cyclodextrin.

15. The process according to claim 14 , wherein the sulfonyl chloride is selected from the group comprising methanesulfonyl chloride, ethanesulfonyl chloride, allylsulfonyl chloride, 1-propanesulfonyl chloride, benzenesulfonyl chloride, toluenesulfonyl chloride, 4-ethylbenzenesulfonyl chloride, m-xylene-4-sulfonyl chloride, p-xylene-2-sulfonyl chloride, 4-dodecylbenzenesulfonyl chloride, 2-mesitylenesulfonyl chloride, 2,3,5-trichlorobenzenesulfonyl chloride, 2,4-dinitrobenzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, 4-chlorobenzenesulfonyl chloride, heptadecafluorooctanesulfonyl chloride, 1-naphthalenesulfonyl chloride, 2-naphthalenesulfonyl chloride, 1,3,6-naphthalenetrisulfonyl chloride, 2,6-naphthalenedisulfonyl chloride, 1,5-naphthalenedisulfonyl chloride, 1-pyrenesulfonyl chloride, and/or mixtures thereof.

16. The process according to claim 14 , wherein the sulfonyl chloride is methanesulfonyl chloride.

17. The process according to claim 14 , wherein the tertiary amide compound is selected from the group comprising N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone, and/or mixtures thereof.

18. The process according to claim 16 , wherein the tertiary amide is N,N-dimethylformamide.

19. The process according to claim 14 , wherein the reaction between the Vilsmeier reagent and γ-cyclodextrin of step (b) is carried out in the presence of a chloride salt selected from the group comprising lithium chloride, sodium chloride, potassium chloride, cesium chloride, magnesium chloride, calcium chloride, a quaternary ammonium chloride, and/or mixtures thereof.

20. The process according to claim 18 , wherein the chloride salt is lithium chloride.

21. The process according to claim 2 , further comprising the purification of Sugammadex sodium by recrystallization or slurrying in mixtures of water and methanol or ethanol, optionally also using heptane.

22. The process according to claim 4 , wherein the mono-sodium salt of formula (IV-A) is characterized by having X-ray powder diffraction (XRPD) pattern further comprising peaks 6.1, 6.6, 24.9, 27.6, 30.2, 30.7 and 37.7±0.2° 2-theta (2θ).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2020
From: PUIG SERRANO, JORDI; BOSCH I LLADO, JORDI; NG CHOI, ITENG; DURAN LÓPEZ, ERNESTO
To: MEDICHEM, S.A.
Reel/Frame 052732/0430 →
Priority Claims (1)
EP 17382802 · Nov 27, 2017 · regional
Continuity (1)
Related Publication 20200377621A1 · Dec 3, 2020